Literature DB >> 20485255

Colon cancer screening in 2010: an up-date.

A V Weizman1, G C Nguyen.   

Abstract

Colorectal cancer is among the most common cancers worldwide. The prognosis for limited disease is excellent; however, it becomes poor for more advanced disease. The majority of colorectal cancers arise from premalignant adenomatous polyps. This makes the detection of polyps and early carcinoma an attractive screening strategy. This article will review the current tests available for screening for colorectal cancer. These include stool based tests (guaiac-based fecal occult blood tests, immunochemical fecal tests, stool DNA panel), radiologic tests (double contrast barium enema and computed tomography colonography), and endoscopy (flexible sigmoidoscopy and colonoscopy). The current use of these tests in population-based screening programs and the most recent screening guidelines from the largest advisory groups in North America and Europe will be discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20485255

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  10 in total

1.  Dietary inflammatory index and risk of colorectal cancer in the Iowa Women's Health Study.

Authors:  Nitin Shivappa; Anna E Prizment; Cindy K Blair; David R Jacobs; Susan E Steck; James R Hébert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-25       Impact factor: 4.254

2.  Elevated serum DAND5 is associated with metastasis and predicts poor prognosis in colorectal cancer.

Authors:  Xiaofei Miao; Ye Zhang; Jialin Sun; Songkui Cui; Qingyang Meng; Kuiyu Zhu; Xingqian Hu; Tong Wang
Journal:  United European Gastroenterol J       Date:  2016-10-12       Impact factor: 4.623

3.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.

Authors:  Yuji Toiyama; Masanobu Takahashi; Keun Hur; Takeshi Nagasaka; Koji Tanaka; Yasuhiro Inoue; Masato Kusunoki; C Richard Boland; Ajay Goel
Journal:  J Natl Cancer Inst       Date:  2013-05-23       Impact factor: 13.506

Review 4.  An update on microRNAs as colorectal cancer biomarkers: where are we and what's next?

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Ajay Goel
Journal:  Expert Rev Mol Diagn       Date:  2014-08-28       Impact factor: 5.225

Review 5.  Epigenetic Biomarkers for the Early Detection of Gastrointestinal Cancer.

Authors:  Hui-Mi Chen; Jing-Yua Fang
Journal:  Gastrointest Tumors       Date:  2015-04-15

6.  ZC3H12A Expression in Different Stages of Colorectal Cancer.

Authors:  Tao Chen; Di Du; Jian Chen; Pinghong Zhou; John N Weinstein; Liqing Yao; Yuexin Liu
Journal:  Oncoscience       Date:  2019-04-02

7.  Diagnostic Value of Combining miRNAs, CEA Measurement and the FOBT in Colorectal Cancer Screening.

Authors:  Xiaodan Li; Rong Chen; Zhifa Li; Bing Luo; Wenyan Geng; Xiaobing Wu
Journal:  Cancer Manag Res       Date:  2020-04-15       Impact factor: 3.989

8.  The Diagnostic and Prognostic Value of Serum lncRNA NEAT1 in Colorectal Cancer.

Authors:  Yong Wang; Dongsheng Zhang; Chuan Zhang; Yueming Sun
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

9.  Serum annexin A2 levels in patients with colon cancer in comparison to healthy controls and in relation to tumor pathology.

Authors:  Ercument Gurluler; Osman Serhat Guner; Latif Volkan Tumay; Nurten Turkel Kucukmetin; Banu Hizli; Abdullah Zorluoglu
Journal:  Med Sci Monit       Date:  2014-10-03

Review 10.  Diagnostic and Prognostic Value of Serum Interleukin-6 in Colorectal Cancer.

Authors:  Jinming Xu; Yao Ye; Honghe Zhang; Maciej Szmitkowski; M J Mäkinen; Peiwei Li; Dajing Xia; Jun Yang; Yihua Wu; Han Wu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.